Published in J Exp Med on August 01, 1995
Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A (2000) 2.83
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Altered immune responses in interleukin 10 transgenic mice. J Exp Med (1997) 1.85
Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. Proc Natl Acad Sci U S A (2007) 1.77
The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses. J Clin Invest (2002) 1.63
Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc Natl Acad Sci U S A (1998) 1.60
A placenta-specific receptor for the fusogenic, endogenous retrovirus-derived, human syncytin-2. Proc Natl Acad Sci U S A (2008) 1.40
Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol (2000) 1.24
Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22
Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res (2011) 1.22
Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A (2010) 1.18
A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med (2000) 1.16
Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunol (2007) 1.11
Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology (2002) 1.04
RNAs in Epstein-Barr virions control early steps of infection. Proc Natl Acad Sci U S A (2012) 1.01
Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun (2002) 0.98
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer (1999) 0.97
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. BMC Cancer (2005) 0.92
DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A (2005) 0.89
Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther (2006) 0.86
A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood (2005) 0.86
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol (1998) 0.85
ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation. Clin Diagn Lab Immunol (1997) 0.79
The Microbiome, Systemic Immune Function, and Allotransplantation. Clin Microbiol Rev (2016) 0.79
Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. J Clin Invest (2003) 0.79
Epstein-Barr virus IL-10 gene expression by a recombinant murine gammaherpesvirus in vivo enhances acute pathogenicity but does not affect latency or reactivation. Herpesviridae (2014) 0.77
PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO. Oncoimmunology (2016) 0.75
Structure-based release analysis of the JC virus agnoprotein regions: A role for the hydrophilic surface of the major alpha helix domain in release. J Cell Physiol (2017) 0.75
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
Biology of natural killer cells. Adv Immunol (1989) 14.77
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol (1988) 12.84
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (1991) 11.04
Interleukin-10. Annu Rev Immunol (1993) 10.14
Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A (1988) 9.35
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med (1993) 8.03
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 7.18
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A (1993) 6.33
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Liver transplantation (1). N Engl J Med (1989) 4.53
Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med (1990) 4.30
Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med (1991) 3.34
Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science (1984) 3.29
IL-10, a novel growth cofactor for mature and immature T cells. J Immunol (1990) 3.02
IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol (1992) 2.94
B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med (1994) 2.85
Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature (1985) 2.48
IL-10: a novel cytotoxic T cell differentiation factor. J Immunol (1991) 2.32
Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature (1984) 2.12
Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol (1994) 2.03
Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med (1993) 1.94
A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A (1993) 1.91
Expression cloning and characterization of a human IL-10 receptor. J Immunol (1994) 1.89
Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol (1992) 1.88
Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med (1994) 1.82
The short unique region of the B95-8 Epstein-Barr virus genome. Virology (1985) 1.73
Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Immunol (1985) 1.61
Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med (1993) 1.37
Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol (1993) 1.31
Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res (1989) 1.30
IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol (1993) 1.27
Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res (1993) 1.19
Interleukin-10 and its receptor. Ther Immunol (1994) 1.18
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther (1994) 1.00
Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol (1988) 0.97
H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity. J Immunol (1988) 0.96
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol (1985) 0.87
Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res (1983) 0.79
Islet cell transplantation facilitated by gene transfer. Transplant Proc (1992) 0.77
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (1991) 11.04
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature (2001) 6.62
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 6.37
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci (2000) 5.53
A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains. Cell (1981) 5.43
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med (1990) 4.30
Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science (1990) 3.70
The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today (1991) 3.61
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med (1991) 3.34
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
DNA sequence of a gene encoding a BALB/c mouse Ld transplantation antigen. Science (1982) 3.17
Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol (2001) 3.13
Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol (2000) 3.05
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 3.05
IL-10, a novel growth cofactor for mature and immature T cells. J Immunol (1990) 3.02
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet (1998) 3.01
IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J (1998) 2.99
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol (1990) 2.79
Lymphotactin: a cytokine that represents a new class of chemokine. Science (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol (1991) 2.71
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol (1998) 2.57
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev (1991) 2.49
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
The retinoblastoma gene product regulates Sp1-mediated transcription. Mol Cell Biol (1992) 2.21
Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int Immunol (1992) 2.20
Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature (1991) 2.12
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int (2006) 2.04
Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition. Proc Natl Acad Sci U S A (1998) 2.01
Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther (2000) 2.01
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene (1993) 1.95
Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature (1992) 1.93
A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A (1993) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Expression cloning and characterization of a human IL-10 receptor. J Immunol (1994) 1.89
In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum (1997) 1.87
Altered immune responses in interleukin 10 transgenic mice. J Exp Med (1997) 1.85
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 1.81
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol (1989) 1.75
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol (1993) 1.69
Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A (1993) 1.65
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem (1996) 1.64
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Ther (1995) 1.63
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci U S A (1991) 1.63
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Expression and isolation of antimicrobial small molecules from soil DNA libraries. J Mol Microbiol Biotechnol (2001) 1.60
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
Isolation and expression of cDNA clones encoding a human receptor for IgG (Fc gamma RII). J Exp Med (1987) 1.60
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol (1990) 1.59
Endoscopic screening of early esophageal cancer with the Lugol dye method in patients with head and neck cancers. Cancer (1990) 1.58
Expression of human inducible nitric oxide synthase in a tetrahydrobiopterin (H4B)-deficient cell line: H4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci U S A (1995) 1.56
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg (1981) 1.54
Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A (1998) 1.54
Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther (2002) 1.53
A proapoptotic peptide for the treatment of solid tumors. Cancer Res (2001) 1.52
Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phila Pa 1976) (1999) 1.51
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 1.50
Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol (2000) 1.50
Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation. J Immunol (1988) 1.50
Telomerase activity in normal human epithelial cells. Oncogene (1996) 1.50
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Expression of IgD may use both DNA rearrangement and RNA splicing mechanisms. Proc Natl Acad Sci U S A (1981) 1.48
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay. Clin Chem (1998) 1.46
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem (1995) 1.46
The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol (1997) 1.46
In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J Immunol (1980) 1.44
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1987) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem (2000) 1.42
Adenoviral transduction of human osteoblastic cell cultures: a new perspective for gene therapy of bone diseases. Acta Orthop Scand (1999) 1.42
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol (1989) 1.41